Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Intangibles (2019 - 2025)

Eton Pharmaceuticals' Intangibles history spans 6 years, with the latest figure at $34.9 million for Q4 2024.

  • For Q4 2024, Intangibles rose 636.04% year-over-year to $34.9 million; the TTM value through Dec 2024 reached $34.9 million, up 636.04%, while the annual FY2024 figure was $34.9 million, 636.04% up from the prior year.
  • Intangibles for Q4 2024 was $34.9 million at Eton Pharmaceuticals, up from $6.1 million in the prior quarter.
  • Across five years, Intangibles topped out at $34.9 million in Q4 2024 and bottomed at $463000.0 in Q3 2021.
  • The 5-year median for Intangibles is $3.1 million (2022), against an average of $4.7 million.
  • The largest annual shift saw Intangibles dropped 24.35% in 2021 before it surged 974.08% in 2022.
  • A 5-year view of Intangibles shows it stood at $575000.0 in 2020, then soared by 529.74% to $3.6 million in 2021, then skyrocketed by 31.29% to $4.8 million in 2022, then dropped by 0.32% to $4.7 million in 2023, then surged by 636.04% to $34.9 million in 2024.
  • Per Business Quant, the three most recent readings for ETON's Intangibles are $34.9 million (Q4 2024), $6.1 million (Q2 2024), and $4.7 million (Q4 2023).